Avalon GloboCare Teams up with Weill Cornell Medicine to Establish Joint Translational Research Initiative

Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has jointly established a translational research training program with the Shahin Rafii Laboratory of the Division of Regenerative Medicine at Weill Cornell Medicine, New York.

As quoted in the press release:

“This translational research and training program will synergize Dr. Rafii’s world-class stem cell facility at Weill Cornell Medicine and our immense clinical resources at the Lu Daopei hospital network with a common objective of stimulating and accelerating cell-based technology innovation and development, process standardization, as well as knowledge exchange in regenerative medicine,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp. “We are very proud to initiate this endeavor with an overarching goal of integrating premium research and clinical resources worldwide to advance breakthrough, safer, and more effective cell-based therapeutics,” added Dr. Jin.

Click here to read the full press release.